7results about How to "Huge development potential" patented technology

The invention relates to the technical field of medicines, and provides a cyclic peptide compound, a pharmaceutical composition and application. The cyclopeptide compound provided by the invention has a structure as shown in a formula I. The cyclopeptide compound has remarkable EphA2 targeting affinity, has remarkable drug development potential on an EphA2 target spot, and has a wide application prospect in diagnosis, prevention and treatment of related diseases with high expression of EphA2. The result of the embodiment shows that the affinity constant KD of the cyclopeptide compound provided by the invention and an EphA2 target is between 1 * 10 <-9 > M and 1 * 10 <-7 > M, the cyclopeptide compound is difficult to dissociate after being combined with the target, and meanwhile, the cyclopeptide compound has very strong competitive capacity for a ligand Ephrin-A1 of the EphA2 target. # imgabs0 #

The invention discloses an endophytic fungus, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.41218. The endophytic fungus has the advantages that the endophytic fungus can be used for preparing a culture medium; the endophytic fungus strain PG-2 can increase the antioxidant enzyme activity of monocotyledons (high wheatgrass and triticale) and dicotyledons (green vegetables and calcium vegetables), promote the accumulation of permeability regulating substances and reduce the content of malondialdehyde in the body. The PG-2 is a drought-resistant strain which has oxidation resistance and drought resistance and can promote plant growth, and has huge development potential in agricultural production.

The invention discloses application of USP15 in preparation of a bladder cancer radiotherapy sensitizer, and belongs to the technical field of biological medicine. The objective of the invention is to improve the radiotherapy sensitivity of bladder cancer. The invention relates to an application of USP15 in preparation of a bladder cancer radiotherapy sensitizer. The USP15 is used for preparing the bladder cancer radiotherapy sensitizer. The radiotherapy sensitivity of the bladder cancer is improved by overexpressing the USP15. The USP15 can regulate and control the stability of FIS1 protein through ubiquitination modification so as to inhibit the mitochondrial function, and the activation of the regulation and control pathway is the core mechanism of the USP15 for exerting the radiotherapy sensitization effect. In conclusion, the invention not only provides a new thought for molecular mechanism research of bladder cancer radiotherapy sensitization, but also provides a potential strategy for treatment of clinical radiotherapy resistant bladder cancer patients, and has important drug development value and clinical application prospect.

This invention belongs to the field of plant tissue culture technology, specifically disclosing a method for producing Polygonatum polysaccharides using Polygonatum yunnanense tissue culture, comprising the following steps: explant disinfection, callus induction, callus proliferation and induction culture: selecting vigorous callus tissue, transferring it to a culture medium: White medium + 2,4-D 1.5 mg / L + VC 20 mg / L + sucrose 40 g / L + 30 mg / L inducer + agar 6 g / L, pH 5.8, after culture, collecting the callus, drying it, and then extracting Polygonatum yunnanense polysaccharides; the inducer is Polygonatum yunnanense endophytic basidiomycetes (… Talaromyces sp. The fermentation broth extract of HJF23; the HJF23 preservation number is CCTCC NO: M2021344. This invention not only realizes the efficient biosynthesis of Polygonatum yunnanense polysaccharide, but also significantly enhances its functional activity.

The invention discloses an active peptide capable of directionally inducing IPSCS cracking, a preparation method of the active peptide and application of the active peptide in a preparation for repairing liver injury. Experiments prove that the active peptide provided by the invention has a remarkable protective effect on a liver injury model induced by cyclophosphamide and shows a definite anti-oxidative stress effect. The result shows that a key path of chemotherapy injury can be intervened from the source by simulating or enhancing an endogenous protection mechanism of the liver. Compared with the existing exogenous synthetic drugs or single-component natural products, the product provided by the invention has the potential advantages of more comprehensive action mechanism and better biogenic property. Meanwhile, the extract is derived from directionally differentiated functional cells, and a brand new thought and material basis are provided for developing a novel chemotherapy liver protective agent which does not affect the chemotherapy curative effect and has good biocompatibility.

The invention discloses a preparation method and application of a mixed substituted polyphosphazene gas separation membrane, and belongs to the technical field of gas separation. The preparation method comprises the following steps: 1) carrying out ring-opening polymerization of phosphonitrilic chloride trimer by a chemical reaction method to obtain an intermediate polydichlorophosphazene, 2) introducing aniline and n-octylamine with different molar contents (X) into the polyphosphazene to synthesize polyaniline-n-octylamine phosphazene (PBAPX / POA (1-X), the range of X being 0.30-0.05), 3) carrying out blade coating on a polytetrafluoroethylene (PVDF) support layer by a blade coating method, and 4) carrying out drying to obtain the polyaniline-n-octylamine phosphazene composite material. And preparing the PBAPX / POA (1-X) / PVDF gas separation composite membrane. The polyphosphazene gas separation membrane prepared by adopting the mixed substitution method is compact and uniform in surface, tight in connection between the supporting layer and the separation layer, free of obvious defects and excellent in separation and membrane forming performance.

The invention belongs to the field of drugs for inflammatory dermatosis, and discloses an application of myrcene in preparation of drugs for inflammatory dermatosis, which comprises the following steps: combining a mouse AD model (DNCB) with human epidermal keratinocytes (NHEK) and mouse macrophages (RAW264.7); the improvement effect of the MYR is evaluated by adopting histology and immunofluorescence technologies; by integrating transcriptomics and proteomics analysis, the molecular mechanism of MYR for relieving AD symptoms is clarified, and the causal relationship is verified by using a pharmacological inhibitor. The conclusion of the invention is as follows: Myrcene alleviates AD sample inflammation by inhibiting FAK / Src-YAP / TAZ axis. A repeatable mechanism framework is established by the data, and the natural monoterpenoids are associated with biomechanical-nuclear signal transduction and innate immune regulation in AD.